<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36716024</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries.</ArticleTitle><Pagination><StartPage>279</StartPage><EndPage>286</EndPage><MedlinePgn>279-286</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.5128</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Diagnostic incidence data for syndromes associated with frontotemporal lobar degeneration (FTLD) in multinational studies are urgent in light of upcoming therapeutic approaches.</AbstractText><AbstractText Label="OBJECTIVE">To assess the incidence of FTLD across Europe.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The Frontotemporal Dementia Incidence European Research Study (FRONTIERS) was a retrospective cohort study conducted from June 1, 2018, to May 31, 2019, using a population-based registry from 13 tertiary FTLD research clinics from the UK, the Netherlands, Finland, Sweden, Spain, Bulgaria, Serbia, Germany, and Italy and including all new FTLD-associated cases during the study period, with a combined catchment population of 11&#x202f;023&#x202f;643 person-years. Included patients fulfilled criteria for the behavioral variant of frontotemporal dementia (BVFTD), the nonfluent variant or semantic variant of primary progressive aphasia (PPA), unspecified PPA, progressive supranuclear palsy, corticobasal syndrome, or frontotemporal dementia with amyotrophic lateral sclerosis (FTD-ALS). Data were analyzed from July 19 to December 7, 2021.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Random-intercept Poisson models were used to obtain estimates of the European FTLD incidence rate accounting for geographic heterogeneity.</AbstractText><AbstractText Label="RESULTS">Based on 267 identified cases (mean [SD] patient age, 66.70 [9.02] years; 156 males [58.43%]), the estimated annual incidence rate for FTLD in Europe was 2.36 cases per 100&#x202f;000 person-years (95% CI, 1.59-3.51 cases per 100&#x202f;000 person-years). There was a progressive increase in FTLD incidence across age, reaching its peak at the age of 71 years, with 13.09 cases per 100 000 person-years (95% CI, 8.46-18.93 cases per 100 000 person-years) among men and 7.88 cases per 100 000 person-years (95% CI, 5.39-11.60 cases per 100 000 person-years) among women. Overall, the incidence was higher among men (2.84 cases per 100&#x202f;000 person-years; 95% CI, 1.88-4.27 cases per 100&#x202f;000 person-years) than among women (1.91 cases per 100&#x202f;000 person-years; 95% CI, 1.26-2.91 cases per 100&#x202f;000 person-years). BVFTD was the most common phenotype (107 cases [40.07%]), followed by PPA (76 [28.46%]) and extrapyramidal phenotypes (69 [25.84%]). FTD-ALS was the rarest phenotype (15 cases [5.62%]). A total of 95 patients with FTLD (35.58%) had a family history of dementia. The estimated number of new FTLD cases per year in Europe was 12&#x202f;057.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The findings suggest that FTLD-associated syndromes are more common than previously recognized, and diagnosis should be considered at any age. Improved knowledge of FTLD incidence may contribute to appropriate health and social care planning and in the design of future clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Logroscino</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Diseases and the Aging Brain, University of Bari-Aldo Moro, Bari at Pia Fondazione Cardinale Giovanni Panico, Tricase, Lecce, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccininni</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Public Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Stroke Research Berlin, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit for Hereditary Dementia, Theme Aging, Karolinska University Hospital-Solna, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Fermin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Martin Luther University, University Hospital, Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remes</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Center, Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurosciences, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, MRC Cognition and Brain Sciences Unit, and Cambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seelaar</LastName><ForeName>Harro</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center Erasmus MC, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solje</LastName><ForeName>Eino</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroCenter, Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefanova</LastName><ForeName>Elka</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Neurology Clinic, University Clinical Center, University of Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traykov</LastName><ForeName>Latchezar</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Alexandrovska University Hospital, Department of Neurology, Medical University Sofia, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jelic</LastName><ForeName>Vesna</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Theme Inflammation and Aging, Medical Unit Aging Brain, Karolinska University Hospital Huddinge, Solna, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rydell</LastName><ForeName>Melissa Taheri</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pender</LastName><ForeName>Niall</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderl-Straub</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barandiaran</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabilondo</LastName><ForeName>Alazne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Center, Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurocenter, Neurology, Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murley</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, MRC Cognition and Brain Sciences Unit, and Cambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rittman</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, MRC Cognition and Brain Sciences Unit, and Cambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Ende</LastName><ForeName>Emma L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center Erasmus MC, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center Erasmus MC, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartikainen</LastName><ForeName>P&#xe4;ivi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>NeuroCenter, Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stojmenovic</LastName><ForeName>Gorana Mandic</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Neurology Clinic, University Clinical Center, University of Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehrabian</LastName><ForeName>Shima</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Alexandrovska University Hospital, Department of Neurology, Medical University Sofia, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benussi</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alberici</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Neurology Unit, Azienda Socio Sanitaria Territoriale Spedali Civili Brescia and University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dell'Abate</LastName><ForeName>Maria Teresa</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Diseases and the Aging Brain, University of Bari-Aldo Moro, Bari at Pia Fondazione Cardinale Giovanni Panico, Tricase, Lecce, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zecca</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Diseases and the Aging Brain, University of Bari-Aldo Moro, Bari at Pia Fondazione Cardinale Giovanni Panico, Tricase, Lecce, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Neurology Unit, Azienda Socio Sanitaria Territoriale Spedali Civili Brescia and University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>FRONTIERS group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105597119</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00005/12</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SUAG/051 G101400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BRC-1215-20014</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Logroscino reported receiving grants from Regione Puglia during the conduct of the study. Dr Piccininni reported receiving funding from Novartis Pharma and a research grant from the Center for Stroke Research Berlin (private donations) and being an associate editor for <i>Frontiers in Epidemiology</i>. Dr Hardiman reported receiving personal fees for serving as editor of <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> outside the submitted work. Dr Moreno reported receiving grants from the Instituto de Salud Carlos III and the Tau Consortium outside the submitted work. Dr Otto reported receiving grants from the German Federal Ministry of Education and Research (BMBF)&#x2013;German Consortium for Frontotemporal Lobar Degeneration and BMBF&#x2013;Genfi-Prox during the conduct of the study. Dr Remes reported receiving grants from the Academy of Finland during the conduct of the study. Dr Rowe reported receiving grants from the National Institute for Health Research (NIHR), the Medical Research Council, and the Cambridge Centre for Parkinson-Plus during the conduct of the study; grants from Wellcome Trust and Dementias Platform UK (with indirect funding from Janssen, GSK, Lilly, and AstraZeneca) outside the submitted work; and personal fees from Asceneuron, Astex, SV Health, CuraSen, and UCB Pharma Ltd outside the submitted work. Dr Stefanova reported receiving personal fees from Roche for lecturing and conference fees from Teva Actavis. Dr Pender reported receiving personal fees (speaking and honoraria) from the Dementia Academy and Novartis and grants from the Huntington&#x2019;s Disease Association of Ireland outside the submitted work. Dr Murley reported receiving grants from the Holt Fellowship during the conduct of the study. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Belezhanska</LastName><ForeName>Diyana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bianchetti</LastName><ForeName>Angelo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Binetti</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cotelli</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cotelli</LastName><ForeName>Maria Sofia</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dreharova</LastName><ForeName>Irena</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Filardi</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fostinelli</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghidoni</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gnoni</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nacheva</LastName><ForeName>Genoveva</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novakovi&#x107;</LastName><ForeName>Ivana</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Popivanov</LastName><ForeName>Ivo</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raycheva</LastName><ForeName>Margarita</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stockton</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoyanova</LastName><ForeName>Katya</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suhonen</LastName><ForeName>Noora-Maria</ForeName><Initials>NM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tainta</LastName><ForeName>Mikel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toncheva</LastName><ForeName>Draga</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urso</LastName><ForeName>Daniele</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zlatareva</LastName><ForeName>Dora</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zulaica</LastName><ForeName>Miren</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>30</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36716024</ArticleId><ArticleId IdType="pmc">PMC9887528</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.5128</ArticleId><ArticleId IdType="pii">2800415</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain. 2005;128(Pt 9):1996-2005. doi:10.1093/brain/awh598</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh598</ArticleId><ArticleId IdType="pubmed">16033782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Neumann M, Bigio EH, et al. . Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119(1):1-4. doi:10.1007/s00401-009-0612-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0612-2</ArticleId><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Lashley T, Schott JM, et al. . Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain. 2011;134(Pt 9):2565-2581. doi:10.1093/brain/awr198</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr198</ArticleId><ArticleId IdType="pmc">PMC3170537</ArticleId><ArticleId IdType="pubmed">21908872</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477. doi:10.1093/brain/awr179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, Respondek G, Stamelou M, et al. ; Movement Disorder Society-endorsed PSP Study Group . Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26987</ArticleId><ArticleId IdType="pmc">PMC5516529</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong MJ, Litvan I, Lang AE, et al. . Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503. doi:10.1212/WNL.0b013e31827f0fd1</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31827f0fd1</ArticleId><ArticleId IdType="pmc">PMC3590050</ArticleId><ArticleId IdType="pubmed">23359374</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. . Amyotrophic lateral sclerosis&#x2013;frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3-4):153-174. doi:10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n J, Ashton NJ, Blennow K, Zetterberg H. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Curr Opin Neurobiol. 2020;61:29-39. doi:10.1016/j.conb.2019.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2019.11.019</ArticleId><ArticleId IdType="pubmed">31838254</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi M, Agosta F. MRI of non-Alzheimer&#x2019;s dementia: current and emerging knowledge. Curr Opin Neurol. 2018;31(4):405-414. doi:10.1097/WCO.0000000000000571</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000571</ArticleId><ArticleId IdType="pubmed">29746400</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Piccininni M, Binetti G, et al. . Incidence of frontotemporal lobar degeneration in Italy: the Salento-Brescia Registry study. Neurology. 2019;92(20):e2355-e2363. doi:10.1212/WNL.0000000000007498</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007498</ArticleId><ArticleId IdType="pubmed">30979859</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle-Gilchrist ITS, Dick KM, Patterson K, et al. . Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86(18):1736-1743. doi:10.1212/WNL.0000000000002638</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002638</ArticleId><ArticleId IdType="pmc">PMC4854589</ArticleId><ArticleId IdType="pubmed">27037234</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615-1621. doi:10.1212/WNL.58.11.1615</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.11.1615</ArticleId><ArticleId IdType="pubmed">12058088</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Petersen RC, Edland SD, Cha RH, Rocca WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology. 2004;62(3):506-508. doi:10.1212/01.WNL.0000106827.39764.7E</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000106827.39764.7E</ArticleId><ArticleId IdType="pubmed">14872045</ArticleId></ArticleIdList></Reference><Reference><Citation>Garre-Olmo J, Gen&#xed;s Batlle D, del Mar Fern&#xe1;ndez M, et al. ; Registry of Dementia of Girona Study Group (ReDeGi Study Group) . Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology. 2010;75(14):1249-1255. doi:10.1212/WNL.0b013e3181f5d4c4</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f5d4c4</ArticleId><ArticleId IdType="pubmed">20810999</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F, Lozupone M, Seripa D, et al. . Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat Rev Neurol. 2020;16(4):213-228. doi:10.1038/s41582-020-0330-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0330-x</ArticleId><ArticleId IdType="pubmed">32203398</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Dell&#x2019;Era V, Cosseddu M, et al. . Transcranial stimulation in frontotemporal dementia: a randomized, double-blind, sham-controlled trial. Alzheimers Dement (N Y). 2020;6(1):e12033. doi:10.1002/trc2.12033</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12033</ArticleId><ArticleId IdType="pmc">PMC7253155</ArticleId><ArticleId IdType="pubmed">32490143</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsapkini K, Webster KT, Ficek BN, et al. . Electrical brain stimulation in different variants of primary progressive aphasia: a randomized clinical trial. Alzheimers Dement (N Y). 2018;4:461-472. doi:10.1016/j.trci.2018.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2018.08.002</ArticleId><ArticleId IdType="pmc">PMC6153381</ArticleId><ArticleId IdType="pubmed">30258975</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotelli M, Manenti R, Petesi M, et al. . Treatment of primary progressive aphasias by transcranial direct current stimulation combined with language training. J Alzheimers Dis. 2014;39(4):799-808. doi:10.3233/JAD-131427</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-131427</ArticleId><ArticleId IdType="pubmed">24296814</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Graff C, Hardiman O, et al. . Frontotemporal Dementia Incidence European Research Study&#x2014;FRONTIERS: rationale and design. Alzheimers Dement. 2022;18(3):498-506. doi:10.1002/alz.12414</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12414</ArticleId><ArticleId IdType="pmc">PMC9291221</ArticleId><ArticleId IdType="pubmed">34338439</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Brayne C, Feigin VL, et al. . Explanation and elaboration of the Standards of Reporting of Neurological Disorders Checklist: a guideline for the reporting of incidence and prevalence studies in neuroepidemiology. Neuroepidemiology. 2015;45(2):113-137. doi:10.1159/000439132</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000439132</ArticleId><ArticleId IdType="pubmed">26390430</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Alberici A, Samra K, et al. ; GENFI Consortium . Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimers Dement. 2022;18(7):1408-1423. doi:10.1002/alz.12485</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12485</ArticleId><ArticleId IdType="pubmed">34874596</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JS, Farmer JM, Wood EM, et al. . Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65(11):1817-1819. doi:10.1212/01.wnl.0000187068.92184.63</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000187068.92184.63</ArticleId><ArticleId IdType="pubmed">16344531</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Kramer JH, Boeve BF, et al. . Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008;131(Pt 11):2957-2968. doi:10.1093/brain/awn234</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn234</ArticleId><ArticleId IdType="pmc">PMC2725027</ArticleId><ArticleId IdType="pubmed">18829698</ArticleId></ArticleIdList></Reference><Reference><Citation>European Commission. Revision of the European Standard Population: report of Eurostat&#x2019;s task force. 2013. Accessed January 14, 2022. https://ec.europa.eu/eurostat/documents/3859598/5926869/KS-RA-13-028-EN.PDF/e713fa79-1add-44e8-b23d-5e8fa09b3f8f</Citation></Reference><Reference><Citation>Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med. 1997;16(7):791-801. doi:10.1002/(SICI)1097-0258(19970415)16:7&lt;791::AID-SIM500&gt;3.0.CO;2-#</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19970415)16:7&lt;791::AID-SIM500&gt;3.0.CO;2-#</ArticleId><ArticleId IdType="pubmed">9131766</ArticleId></ArticleIdList></Reference><Reference><Citation>R Project for Statistical Computing. Index of /src/contrib/Archive/dsr. Accessed January 14, 2022. https://cran.r-project.org/src/contrib/Archive/dsr/</Citation></Reference><Reference><Citation>Eurostat. European Union. Accessed December 14, 2022. https://ec.europa.eu/eurostat/web/main/eurostat/web/main/help/faq/data-services</Citation></Reference><Reference><Citation>Rostalski H, Korhonen V, Kuulasmaa T, et al. . A novel genetic marker for the C9orf72 repeat expansion in the Finnish population. J Alzheimers Dis. 2021;83(3):1325-1332. doi:10.3233/JAD-210599</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-210599</ArticleId><ArticleId IdType="pubmed">34397416</ArticleId></ArticleIdList></Reference><Reference><Citation>Turcano P, Stang CD, Mielke MM, et al. . Incidence of frontotemporal disorders in Olmsted County: a population-based study (1995&#x2013;2010). Alzheimers Dement. 2020;16(3):482-490. doi:10.1016/j.jalz.2019.08.199</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.08.199</ArticleId><ArticleId IdType="pmc">PMC7067641</ArticleId><ArticleId IdType="pubmed">31784373</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, et al. ; EURALS . Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81(4):385-390. doi:10.1136/jnnp.2009.183525</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ill&#xe1;n-Gala I, Casaletto KB, Borrego-&#xc9;cija S, et al. . Sex differences in the behavioral variant of frontotemporal dementia: a new window to executive and behavioral reserve. Alzheimers Dement. 2021;17(8):1329-1341. doi:10.1002/alz.12299</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12299</ArticleId><ArticleId IdType="pmc">PMC8364861</ArticleId><ArticleId IdType="pubmed">33590953</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Guerreiro R, Vandrovcova J, et al. . The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73(18):1451-1456. doi:10.1212/WNL.0b013e3181bf997a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bf997a</ArticleId><ArticleId IdType="pmc">PMC2779007</ArticleId><ArticleId IdType="pubmed">19884572</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, et al. . Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal Dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 2015;14(3):253-262. doi:10.1016/S1474-4422(14)70324-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducharme S, Dols A, Laforce R, et al. . Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020;143(6):1632-1650. doi:10.1093/brain/awaa018</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa018</ArticleId><ArticleId IdType="pmc">PMC7849953</ArticleId><ArticleId IdType="pubmed">32129844</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Kurth T, Piccininni M. The reconstructed cohort design: a method to study rare neurodegenerative diseases in population-based settings. Neuroepidemiology. 2020;54(2):114-122. doi:10.1159/000502863</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000502863</ArticleId><ArticleId IdType="pubmed">31910416</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>